DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice

Cancer Gene Therapy

Volumn 15, Issue 2, 2008, Pages 108-114

  Curcio, C ^a   Khan, A S ^b   Amici, A ^c   Spadaro, M ^a   Quaglino, E ^a   Cavallo, F ^a   Forni, G ^a   Draghia Akli, R ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b VGX Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Cancer vaccine; Electroporation; Her 2 neu; Plasmid

Indexed keywords

CANCER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DNA IMMUNIZATION; DOSE RESPONSE; DRUG EFFICACY; ELECTROPORATION; FEMALE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; CANCER VACCINES; ELECTROPORATION; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PLASMIDS; RATS; VACCINES, DNA;

MUS; MUS MUSCULUS; RATTUS;

EID: 38349056826     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701106     Document Type: Article

References (33)

1. Brown PA, Davis WC, Draghia-Akli R. Immune enhancing effects of growth hormone releasing hormone delivered by plasmid injection and electroporation. Mol Ther 2004; 10: 644-651.
2. Draghia-Akli R, Fiorotto ML. A new plasmid-mediated approach to supplement somatotropin production in pigs. J Anim Sci 2004; 82: E264-E269.
3. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation- enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006; 6: 243-273.
4. Khan AS, Pope MA, Draghia-Akli R. Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol 2005; 24: 810-818.
5. Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 2004; 15: 189-201.
6. Fattori E, Cappelletti M, Zampaglione I, Mennuni C, Calvaruso F, Arcuri M et al. Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 2005; 7: 228-236.
7. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6: 204-216.
8. Stan R, Wolchok JD, Cohen AD. DNA vaccines against cancer. Hematol Oncol Clin North Am 2006; 20: 613-636.
9. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371-387.
10. Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17: 890-897.
11. Di CE, Diodoro MG, Boggio K, Modesti A, Modesti M, Nanni P et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 1999; 79: 1261-1269.
12. Lollini PL, Nicoletti G, Landuzzi L, De GC, Rossi I, Di CE et al. Downregulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int J Cancer 1998; 77: 937-941.
13. Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003; 170: 4273-4280.
14. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di CE et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004; 64: 2858-2864.
15. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-5142.
16. Ritchie DS, Hermans IF, Lumsden JM, Scanga CB, Roberts JM, Yang J et al. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Methods 2000; 246: 109-117.
17. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-1343.
18. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P et al. Immunosurveillance of Erb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66: 7734-7740.
19. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006; 177: 7626-7633.
20. Pannellini T, Forni G, Musiani P. Immunobiology of her-2/neu transgenic mice. Breast Dis 2004; 20: 33-42.
21. Babiuk S, Baca-Estrada M, Foldvari M, Storms M, Rabussay D, Widera G et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20: 3399.
22. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Therapy 2004; 11: 711-721.
23. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115-121.
24. Spadaro M, Ambrosino E, Iezzi M, Di CE, Sacchetti P, Curcio C et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005; 11: 1941-1952.
25. Heller R, Gilbert R, Jaroszeski MJ. Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. Adv Drug Deliv Rev 1997; 26: 185-197.
26. Heller LC, Coppola D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Therapy 2002; 9: 1321-1325.
27. Babiuk S, Baca-Estrada ME, Foldvari M, Middleton DM, Rabussay D, Widera G et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 2004; 110: 1-10.
28. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-1343.
29. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54: 105-115.
30. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102: 2138-2145.
31. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213.
32. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005; 174: 4228-4236.
33. Hebel H, Attra H, Khan A, Draghia-Akli R. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine 2006; 24: 4607-4614.